The relationship between autoimmune pancreatitis and malignancy has been reported. However, the potential risk for cancer in patients with immunoglobulin 4-related sclerosing cholangitis (IgG4-SC) is unclear. The present study aimed to evaluate the incidence of cancer in IgG4-SC patients.
We retrospectively collected clinical data for 121 patients diagnosed with IgG4-SC from 7 hospitals. We calculated the standardized incidence ratio (SIR) of cancer in IgG4-SC patients based on the national cancer rates. The SIR of the period after the diagnosis of IgG4-SC were calculated.
The mean follow-up period was 6.4 years, with 121 IgG4-SC patients. During the follow-up period, 26 patients had cancer, and 29 cancers were diagnosed. The SIR of cancer after the diagnosis of IgG4-SC was 1.90 (95% confidence interval [CI] 1.67-2.21). The SIR of pancreatic and bile duct cancer was 10.30 and 8.88, respectively. The SIR of cancer in 5 years after diagnosis of IgG4-SC were 2.58, 1.01, and 2.44, respectively.
IgG4-SC patients have a high risk of cancer including pancreatic and bile duct cancer. The risk of cancer was high less 5 years after diagnosis of IgG4-SC. Therefore, IgG4-SC patients may require careful long-term follow-up.
This article is protected by copyright. All rights reserved.
About The Expert
Yusuke Kurita
Yuji Fujita
Yusuke Sekino
Seitaro Watanabe
Akito Iwasaki
Koichi Kagawa
Emiko Tanida
Shin Yagi
Sho Hasegawa
Takamitsu Sato
Kunihiro Hosono
Shingo Kato
Noritoshi Kobayashi
Yasushi Ichikawa
Itaru Endo
Atsushi Nakajima
Kensuke Kubota
References
PubMed